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Fibroblast growth factor 21 
reflects liver fat accumulation 
and dysregulation of signalling 
pathways in the liver of C57BL/6J 
mice
Fenni Rusli1, Joris Deelen2, Evi Andriyani1, Mark V. Boekschoten1, Carolien Lute1,  
Erik B. van den Akker2,3, Michael Müller4, Marian Beekman2 & Wilma T Steegenga1
Fibroblast growth factor 21 (Fgf21) has emerged as a potential plasma marker to diagnose non-
alcoholic fatty liver disease (NAFLD). To study the molecular processes underlying the association of 
plasma Fgf21 with NAFLD, we explored the liver transcriptome data of a mild NAFLD model of aging 
C57BL/6J mice at 12, 24, and 28 months of age. The plasma Fgf21 level significantly correlated with 
intrahepatic triglyceride content. At the molecular level, elevated plasma Fgf21 levels were associated 
with dysregulated metabolic and cancer-related pathways. The up-regulated Fgf21 levels in NAFLD 
were implied to be a protective response against the NAFLD-induced adverse effects, e.g. lipotoxicity, 
oxidative stress and endoplasmic reticulum stress. An in vivo PPARα challenge demonstrated the 
dysregulation of PPARα signalling in the presence of NAFLD, which resulted in a stochastically 
increasing hepatic expression of Fgf21. Notably, elevated plasma Fgf21 was associated with declining 
expression of Klb, Fgf21’s crucial co-receptor, which suggests a resistance to Fgf21. Therefore, 
although liver fat accumulation is a benign stage of NAFLD, the elevated plasma Fgf21 likely indicated 
vulnerability to metabolic stressors that may contribute towards progression to end-stage NAFLD. 
In conclusion, plasma levels of Fgf21 reflect liver fat accumulation and dysregulation of metabolic 
pathways in the liver.
Non-alcoholic fatty liver disease (NAFLD) has been recognised as a hepatic manifestation of metabolic syndrome. 
NAFLD covers a spectrum of liver injuries ranging from fat accumulation in the liver (steatosis) to the more severe 
condition of steatohepatitis (NASH). Considering that NAFLD is currently the most common liver disorder, prev-
alence of which has been reported to be 20–40% in the US1,2, the population would benefit from a diagnosis from 
the early stage of NAFLD. Intervention as simple as weight management through diet and exercise is the most 
effective way leading to reduced liver fat, NASH remission, and also reduction of fibrosis3. However, at present a 
population-based screening tool for NAFLD is still lacking. Serum screening of liver enzymes and a liver ultrasound 
technique have been employed in screenings and clinical studies4, but these procedures are, for different reasons, 
suboptimal. A number of studies have pointed out that the blood-screening test of the commonly analysed liver 
enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
γ -glutamyl-transpeptidase (γ -GT) and albumin, poorly diagnose NAFLD5–8. The ultrasound technique has better 
accuracy than the blood screening test, but is also suboptimal due to the low sensitivity of this method9. Magnetic 
resonance imaging and spectroscopy has a higher sensitivity, but this technique requires specific and expensive 
instruments, which limits its measurement availability. Diagnosis on liver biopsies is the most accurate way to 
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determine the presence of NAFLD, but this procedure is highly invasive and not suitable for population-based 
screening. Hence, new accurate and non-invasive measures are required for the diagnosis of NAFLD.
Recently, fibroblast growth factor 21 (FGF21 (Fgf21 in mice)) has emerged as a potential diagnostic marker 
for NAFLD. Serum FGF21 is found to be elevated in NAFLD patients, as compared to healthy subjects, and 
correlates with hepatic fat content and the degree of liver steatosis4,10–12. Moreover, the performance of FGF21 
has been examined in a 3-year prospective study in China and high serum FGF21 was found to be a determi-
nant of NAFLD, showing an area under curve of receiver operating characteristic (AUROC) of 0.81613. Serum 
FGF21 has also been reported to increase the accuracy of non-alcoholic steatohepatitis (NASH) diagnosis using 
cytokeratin-18 fragment (CK-18)14. Therefore, plasma/serum FGF21 seems a promising diagnostic marker for an 
accurate and non-invasive diagnosis of NAFLD.
FGF21 has multiple metabolic functions, regulating energy homeostasis, glucose-lipid metabolism and insu-
lin sensitivity13. However, it is currently unclear which metabolic functions of FGF21 underlie the association 
of plasma FGF21 level and NAFLD. In the present study, we aim to identify the putative molecular mechanisms 
that underlie the association of plasma FGF21 level with NAFLD. A complicating factor for a human study in this 
field is that the accurate assessment of NAFLD would require liver biopsies from healthy subjects, which is ethi-
cally undesirable. Therefore, we employed a cohort of aging mice to investigate the association between NAFLD, 
which was determined by IHTG level, and plasma Fgf21. The use of a cohort of aging mice, which consists of 
four different age time points, enables us to investigate whether plasma Fgf21 can act as a biomarker at different 
age time points. NAFLD has been reported in subjects of all ages, but particularly in middle to old age (40–65 
years old in human)15, which indicates that NAFLD develops over many years. To create a mice cohort that 
simulates the slow onset of NAFLD, we included a medium-fat diet (MF; 25E% from fat) as a diet that induces 
the development of NAFLD. The energy contribution from fat in this diet group is considered mild, compared 
to other NAFLD-inducing dietary interventions that commonly acutely stimulate NAFLD pathologies within 
several weeks of feeding by applying a high-fat diet (45E% from fat)16,17. In addition to the MF diet, we introduced 
a normal diet (10E% from fat) as the control (C) group and a calorie restriction diet (CR; 30E% reduced feeding 
compared to control group) as a diet regimen that prevents NAFLD. Then, we investigated whether the use of 
plasma Fgf21 as marker for NAFLD in our mice cohort is comparable to what has previously been reported for 
humans. We next searched for the biological processes underlying the association of plasma Fgf21 with NAFLD 
by performing microarray analysis on liver mRNA by using two approaches. First, we searched for pathways and 
upstream regulators associated with plasma Fgf21 by performing a gene co-expression network analysis using 
weighted gene co-expression network analysis (WGCNA)18. In the second approach, we investigated the major 
transcriptional difference in NAFLD by performing gene set enrichment analysis (GSEA), and then determining 
the relevance of Fgf21 in the NAFLD-related pathways. To further investigate PPARα signalling as one of the dys-
regulated pathways, we examined the PPARα response to its agonist at the gene expression level. Since we found 
that some of the mice of 6 months of age displayed a high level of plasma Fgf21 in the absence of elevated IHTG 
levels, we also explored the microarray data to search for the functions of the genes associated with the elevated 
Fgf21 plasma level without accumulation of IHTG.
Materials and Methods
Ethics statement. The animal experiment was approved by the Local Committee for Care and Use of 
Laboratory Animals at Wageningen University (code number: drs-2010151b) and performed in accordance with 
the institutional and national guidelines for the care and use of animals.
Mice aging study. The mice aging study was a part of the IDEAL mice aging cohort that has been described 
in detail previously19,20. Briefly, male C57BL/6J mice (age of 7 weeks) were purchased from Janvier (Cedex, France) 
and were housed in pairs of two in the light and temperature (20 °C)-controlled animal facility of Wageningen 
University (12-hour light/dark cycle, light on at 04.00). The mice were acclimated for 2 weeks, receiving standard 
AIN-93G (Research Diet Services, Wijk bij Duurstede, The Netherlands) upon arrival. All mice were provided 
with ad libitum access to water. The study design is presented in Supplementary Fig. S1. The diet intervention 
started at the age of 9 weeks. The mice were housed individually and randomly distributed into three intervention 
groups: 1) control diet (C, 10E% fat, n = 89) receiving AIN-93W diet ad libitum; 2) calorie restricted diet (CR, 
n = 117) receiving AIN-93W-CR in portions containing 70E% of the mean energy intake compared to the mice 
on the control diet; 3) medium fat diet (MF, 25E% fat, n = 127) receiving AIN-93W-MF ad libitum. AIN-93W-CR 
contains an increased concentration of vitamins and minerals in order to feed these mice the same concentrations 
of micronutrients as the mice receiving the AIN-93W diet and to avoid malnutrition. Portion sizes for the mice 
on the CR were based on food intake of mice on the control diet and adjusted every 6 months. The rations were 
provided each day at 15.30, 30 minutes before the light was switched off. The complete diet compositions are listed 
in Supplementary Table S1 (Research Diet Services, Wijk bij Duurstede, The Netherlands).
The mice were culled at the age of 6, 12, 24 and 28 months. At each sacrifice, 12–18 mice of each intervention 
group were sacrificed between 14.00–17.00 on consecutive days (the remaining mice stayed in the experiment 
and were evaluated at older ages). Mice were paired per dietary intervention group according to body weight at 
sacrifice, so that mock and PPARα agonist Wy-14,643 (Wy) treatment were provided to mice with similar body 
weight. Prior to sacrifice each mouse was first fasted for 4 hours, after which they received an intragastric gavage of 
either solvent (0.5% carboxymethyl cellulose) or Wy dispersed in solvent (160 mg Wy/kg body weight) and were 
fasted again for another 6 hours. Body weight, liver weight, IHTG and 4-hydroxyproline were measured in both 
the mock- and Wy-treated animals. Plasma Fgf21 and liver microarray analysis were performed for mock-treated 
animals only, as Wy substance is a PPARα agonist potentially affecting Fgf21 expression. At the sacrifice, the mice 
were sedated with isoflurane (1.5%) in a mixture of nitrous oxide (70%) and oxygen (30%). Blood samples were 
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collected by cardiac puncture, which was followed by neck dislocation. Weight of various organs was measured and, 
subsequently, organs/tissues were snap-frozen and stored at − 80 °C until further molecular/biochemical analysis.
Measurement of hepatic steatosis and fibrosis. Intrahepatic triglyceride (IHTG) content was deter-
mined in 5% liver homogenates prepared in buffer containing 250 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl 
(pH 7.5), using the triglyceride Liquicolor Monoreagent (Instruchemie, Delfzijl, The Netherlands), according 
to manufacturer’s instruction. The IHTG level was applied as the diagnosis standard of NAFLD using the 5% 
or 50 mg TG per gram liver criterion from Kleiner’s scoring21. Liver fibrosis is represented by 4-hydroxyproline 
content measurement in the liver. The 4-hydroxyproline analysis was performed as previously described in 
Hillebrandt et al.22.
Measurement of plasma Fgf21 level and other plasma markers. The plasma Fgf21 concentration 
was determined using Rat/Mouse FGF-21 ELISA kits (Milipore, cat #EZRMFGF21-26K), according to the manu-
facturer’s instructions. Plasma insulin was measured using a Mouse Adipokine (MADKMAG-71K) kit (Millipore, 
Billerica, MA, USA), according to the manufacturer’s instructions. The cytokeratin-18 plasma concentration was 
measured using Mouse Cytokeratin 18-M30 ELISA kit (Cusabio, Hubei, China).
RNA isolation. Total RNA from liver, tibialis anterior muscle, colon scrapings and epidydimal white adipose 
tissue were isolated using TRIzol reagent (Invitrogen, Breda, The Netherlands), according to the manufacturer’s 
instructions. The RNA was treated with DNAse and purified on columns using the RNeasy microkit (Qiagen, 
Venlo, The Netherlands). RNA concentration was measured on a NanoDrop ND-1000 UV–vis spectrophotome-
ter (Isogen, Maarsen, The Netherlands) and RNA integrity was checked on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Amsterdam, The Netherlands) with 6000 Nano Chips, according to the manufacturer’s instructions. 
RNA was judged as suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, dis-
played no chromosomal peaks or RNA degradation products and had a RNA integrity number (RIN) above 8.0.
Microarray hybridization. Hybridization, washing and scanning of Affymetrix GeneChip Mouse Gene 1.1 
ST arrays were performed according to standard Affymetrix protocols as described previously19,23. Microarray 
analysis was performed in MADMAX, a pipeline for statistical analysis of microarray data24. Arrays were nor-
malized using the Robust Multiarray Average method25,26. Probe sets were defined according to Dai et al.27. In 
this method probes are assigned to unique gene identifiers, in this case Entrez IDs. The probes on the Gene 1.1 
ST arrays represent 21,225 Entrez IDs. For the analysis, only genes having 1) an inter-quartile range of > 0.1 and 
2) an intensity value of > 20 on at least five arrays were taken into account, which resulted in 15,885 genes in the 
dataset. Array data have been submitted to the Gene Expression Omnibus, with accession number GSE84495.
cDNA synthesis and real-time quantitative PCR. The microarray data was validated by real-time quan-
titative PCR (Q-PCR). For each individual sample, single-stranded complementary DNA was synthesized from 
1 μ g of total RNA using the First Strand cDNA Synthesis kit (Thermo Scientific, Landsmeer, The Netherlands), 
following the supplier’s protocol. Q-PCR was performed using SensiMix SYBR No-ROX kit (Bioline, Alphen aan 
de Rijn, The Netherlands) and a CFX384 thermal cycler (Bio-Rad, Veenendaal, The Netherlands). The following 
thermal cycling conditions were used: 2 min at 94 °C, followed by 40 cycles of 94 °C for 15 s and 60 °C for 45 s. 
PCR reactions to validate Fgf21 expression were performed in duplicate and all samples were normalized to Rplp0 
expression. Primer sequences were retrieved from the online PrimerBank database28 and the sequences of the 
primers used are listed in Supplementary Table S2.
Statistical analysis. Data were analysed with GraphPad Prism 5.04. The data were expressed as 
mean ± standard error mean. Comparison between two groups was performed using student t-test, whereas 
comparison between 3 or more groups was performed using ANOVA. Correlation between two parameters 
was presented as Pearson correlation coefficient (r) and p-value. A p-value of < 0.05 was considered significant. 
The receiver operating characteristic (ROC) curve analysis was carried out and the area under the ROC curves 
(AUROCs) were calculated to represent their performance to predict NAFLD. Optimal cut-off points were calcu-
lated for sensitivity and specificity reference (Youden Index).
Hepatic transcriptomics data analysis. For the microarray data analysis, differentially expressed probe 
sets were identified by using linear models (library limma) and the intensity-based moderated t-statistic (IBMT) 
method was applied29,30. Resulting log2 intensities and p-values were used for further descriptive bioinformatic 
analysis of the data. Gene set enrichment analysis (GSEA; http://www.broad.mit.edu/gsea/) was performed in 
MADMAX24. Gene sets with a false discovery rate (FDR) q-value of < 0.01 were considered significantly enriched.
Gene co-expression networks (modules) were constructed using the blockwiseModules R function in 
Weighted Gene Co-expression Network Analysis (WGCNA)18. WGCNA uses a network distance coupled with 
hierarchical clustering and dynamic tree cutting to define modules as branches of a cluster tree. Gene modules, 
which summarize the main patterns of variation, are defined in an unbiased fashion and denoted by colors. The 
first principal component represents the summary of the module and is referred to as the module eigengene 
(ME). MEs were then related to plasma Fgf21 level and other NAFLD-related traits. This approach avoids the 
multiple testing from thousands of individual transcripts to only a number of modules. To explore the functional 
pathways and predicted upstream regulators of the gene modules, Ingenuity pathway analysis (IPA; Ingenuity® 
Systems) was used.
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Results
Control and medium-fat diet groups developed NAFLD at middle and old age. The dietary inter-
ventions exerted pronounced effects on the mice’s body and liver weight, as shown in Fig. 1a,b, respectively. 
During aging, the MF-exposed animals gained the highest body and liver weight, while the CR-fed animals were 
the leanest. The weight gain was accompanied by an increase in IHTG content (Fig. 1c). While the CR-fed animals 
only showed a modest increase over time, the C- and MF-fed animals displayed an elevated IHTG level starting 
at middle-age, i.e. at 12 months. Liver fibrosis, which was represented by the measurement of 4-hydroxyproline 
(4-HP) content in the liver (Fig. 1d), showed to increase at old age (24 and 28 month) in the MF diet group.
The IHTG level was applied as the diagnosis standard of hepatic steatosis using the 5% or 50 mg TG per gram 
liver criterion from Kleiner’s scoring21. The prevalence of hepatic steatosis development in the cohort is depicted 
in Fig. 1e. At the age of 6 months, none of the mice in any of the diet groups developed hepatic steatosis, indicating 
a healthy liver condition at young/mature adult age. Hepatic steatosis development became visible in 12-month 
old mice exposed to C and MF diets, reaching up to 85.7% in the MF diet group. At the 24-month time point, the 
prevalence of hepatic steatosis increased considerably in the control group. At this age over 80% in the C and MF 
diet groups displayed steatosis (Fig. 1e) but at the age of 28 months, a slight decrease of prevalence was observed.
Since a criterion of 4-HP level for hepatic fibrosis diagnosis has not been clearly defined, we adapted the level 
of 4-HP that was reported by Fuchs et al. to be associated with extensive portal fibrosis (equivalent with Ishak 
fibrosis scoring stage 2–3)31. A level of > 0.200 μ g of 4-HP per mg liver was applied as an indication of liver fibro-
sis. Increasing prevalence of hepatic fibrosis was only pronounced in the MF intervention group at 24 and 28 
months of age (Fig. 1f). These results showed that hepatic steatosis occurred in both the C and MF intervention 
groups at the middle-age time point, while hepatic fibrosis in particularly developed in the MF diet group at an 
old age. On the other hand, the CR-fed animals were protected from developing hepatic steatosis and fibrosis.
Plasma Fgf21 reflected the hepatic fat accumulation at middle and old age, but not at mature 
adult age. The results presented in Fig. 2a show that plasma Fgf21 levels of the C- and MF-exposed animals 
were higher than that of the CR-exposed animals at all ages. Noticeably, plasma Fgf21 levels were particularly 
high at 6 months of age in the C and CR diet groups. Next, to examine a specific diet- or age-related effect on 
plasma Fgf21 levels, the correlation with IHTG content was carried out separately by diet and age. The CR diet 
group displayed low IHTG and plasma Fgf21 concentration, while the C and MF groups showed some variation. 
However, overall we did not observe significant correlation in any of the different diet groups (Fig. 2b). On the 
other hand, the comparison by age indicated that, except for the 6-month-old mice, the correlations at different 
ages were comparable (Fig. 2c). Some of the young mice, independent of their diet types, exhibited high plasma 
Fgf21 concentrations despite their low IHTG levels. This observation implies that the plasma Fgf21 concentration 
reflects the hepatic fat accumulation at middle-age (12 months) and old age (24 and 28 months), which results in 
an overall correlation coefficient of 0.52 (p < 0.0001), but performs differently at younger age (Fig. 2d).
Plasma Fgf21 levels reflected liver Fgf21 expression. The gene expression levels of Fgf21 in the 
liver were obtained from the microarray data and revealed that, similar to the plasma Fgf21 levels, the C- and 
MF-exposed animals displayed higher expression levels of Fgf21 (Fig. 3a). Notably, the higher levels of plasma 
Fgf21 at the earliest time point of 6 months were also reflected in the Fgf21 liver expression level. The results 
presented in Fig. 3b show that the plasma Fgf21 levels significantly correlated to hepatic Fgf21 expression levels 
obtained by microarray analysis (r = 0.63, p < 0.0001). This result was confirmed by Q-PCR analysis (r = 0.71, 
p < 0.0001, Supplementary Fig. S2a). These observations indicate that the plasma Fgf21 concentration reflects 
the Fgf21 mRNA levels in liver tissue. In addition, we examined whether plasma Fgf21 increased with body or 
liver weight. Correlation analyses confirmed that plasma Fgf21 had significant positive correlation with body and 
liver weights (Supplementary Fig. S2b,c). As Fgf21 has been reported to be expressed abundantly, not only in the 
liver, but also in other tissue types, we also examined whether the plasma Fgf21 concentrations reflect the Fgf21 
expression levels in epidydimal white adipose tissue (eWAT), tibialis anterior muscle and colon tissue. The results 
presented in Fig. 3c–e show that plasma Fgf21 levels was strongly associated with the liver expression, compared 
to the other tissues. The expression levels of Fgf21 in the muscle and colon were extremely low (Fig. 3d,e). The 
correlation of plasma Fgf21 and expression in eWAT was significant, however, the levels of expression in the 
eWAT were much lower compared to those in the liver tissue (Fig. 3c).
To examine whether plasma Fgf21 in mice indicates hepatic fat accumulation as observed in humans, the mice 
were divided into two groups: those that either developed or did not develop NAFLD according to the IHTG 
criterion of higher or lower than 50 mg TG per gram liver from Kleiner’s scoring21. This resulted in 53 animals 
without NAFLD, which largely consisted of young or CR-fed animals, and 36 animals with NAFLD, which mostly 
consisted of older animals or under the C or MF dietary regimen. The average IHTG contents of the animals with 
and without NAFLD were 111.1 and 22.2 mg TG per gram liver, respectively. The characteristics of animals with 
and without NAFLD are summarized in Supplementary Table S3, showing that the animals with NAFLD had a 
significantly heavier body weight, larger epididymal fat depot, enlarged liver, and lower liver 4-HP content. The 
levels of fasting plasma insulin and the liver injury marker alanine aminotransferase (ALT) were elevated in the 
group of animals with NAFLD.
Subsequently, AUROC analysis was performed using optimal cut-off points determined by the Youden Index 
(plasma Fgf21 > 222.0 pg/ml). The results summarized in Table 1 show that the sensitivity was remarkably high 
at 91.4%, while the specificity was low (57.1%). This resulted in an AUROC of 0.77 (Supplementary Fig. S3a) 
and an accuracy of 71.4% (positive predictive value/PPV of 60.4% and negative predictive value/NPV of 90.3%). 
Since plasma Fgf21 appears to perform differently at the age of 6 months and a previous study of obese children 
indicated that plasma Fgf21 did not provide additional value in predicting NAFLD32, we also tested the Fgf21 
performance in older animals only. When the 6 months old animals were excluded, the AUROC and specificity of 
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Figure 1. Physiological changes induced by the different dietary interventions at the age of 6, 12, 24, and 28 
months. Body weight (a) liver weight (b) and IHTG content (c) dramatically increased over time, except for the 
CR-fed animals which stayed lean. Significance (p-value) of age, diet and interaction were evaluated using two-
way ANOVA. Error bars represent s.e.m. Prevalence of hepatic steatosis (e) and fibrosis (f) in the mice aging 
cohort at different age time points.
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Figure 2. Plasma Fgf21 reflected the hepatic fat accumulation at middle and old age, but not at mature adult 
age. (a) Different plasma Fgf21 levels induced by the dietary interventions at the age of 6, 12, 24, and 28 months. 
Correlation of IHTG and plasma Fgf21 for different dietary interventions (b) and ages (c). (d) Plasma Fgf21 was 
positively correlated with IHTG levels at older ages, while the young 6-month-old mice had elevated plasma 
Fgf21, despite their low IHTG levels (in red symbols). r values were calculated with Pearson’s correlations and 
their significance are indicated in the parentheses.
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Figure 3. Plasma Fgf21 levels were strongly reflected by the expression of Fgf21 in the liver. (a) Different 
expression levels of Fgf21 in the liver induced by the dietary interventions and age. (b) Significant positive 
correlation between plasma Fgf21 and Fgf21 expression in the liver. The association between plasma and 
expression levels of Fgf21 was also compared in other tissue types, (c) epidydimal white adipose tissue (eWAT), 
(d) muscle, and (e) colon tissue. r values were calculated with Pearson’s correlations and their significance are 
indicated in the parentheses.
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Fgf21 were improved to 0.84 (Supplementary Fig. S3b) and 73.5%, while the sensitivity remained high (88.6%). In 
addition, the accuracy was improved to 81.2% (PPV of 77.5% and NPV of 86.2%). Diagnosis using more markers 
commonly yield a better outcome, so we applied combinations of plasma Fgf21 with other plasma or trait markers 
for NAFLD, i.e. plasma ALT, plasma CK-18 and body weight. The performance accuracy described in Table 2 
revealed that the plasma Fgf21 was best combined with plasma ALT (accuracy of 88.4%) or body weight (87.0%), 
while the combination with plasma CK-18 (81.2%) did not improve the performance of Fgf21.
The gene module strongly correlated with the plasma Fgf21 levels contained steatosis- and 
cancer-related genes. To explore the molecular mechanism underlying the involvement of Fgf21 in 
NAFLD development, microarray analysis was performed on mRNA isolated from the livers of the 12, 24, and 
28-month old animals. In the search for the molecular processes underlying the association of plasma Fgf21 with 
NAFLD, the microarray data were analysed by a two-step approach: 1) gene co-expression network analysis using 
WGCNA18 and 2) functional pathways and up-stream regulator analysis were determined by applying Ingenuity 
pathway analysis (IPA) on the co-expression network.
The WGCNA results presented in Fig. 4a, show that 5 modules were created from the hepatic transcrip-
tome data and that 3 of them significantly correlated with plasma Fgf21 (p < 0.05; module grey denotes back-
ground genes outside of modules). The module displaying the most significant correlation with plasma Fgf21 
was MEturquoise (r = − 0.61). Interestingly, cluster differentiation 36 (Cd36), a fatty acid transporter gene 
involved in steatosis development, was identified as the top regulated gene in this module. A correlation analysis 
between plasma Fgf21 and Cd36 expression levels showed a positive significant association (Fig. 4b). Intriguingly, 
beta-Klotho gene (Klb), a co-receptor component that is required for Fgf21 metabolic activity33,34, was included 
in this module. The expression of Klb decreased with the increase of plasma Fgf21 (Fig. 4c). In addition, strong 
inverse correlations with Klb expression were also observed for body weight and IHTG (Supplementary Fig. S4a). 
We also examined plasma Fgf21 correlation with the liver gene expression levels of the 4 members of the Fgf 
receptor family and observed a significant negative correlation with Fgfr2 and Fgfr4 expression, similarly to Klb 
(Supplementary Fig. S4b).
Next, we investigated which biological processes are represented by the genes in the MEturquoise module, 
by using IPA. Figure 4d shows the liver-specific functions with p-value < 0.01 and the 5 most significant reg-
ulators identified by IPA, which were ranked by p-value. Predicted activation/inhibition z-scores are displayed 
when available. The liver-specific functions associated with this module included hepatic steatosis and cholesta-
sis, but the most significant function was the hepatocellular carcinoma (HCC). A number of genes related to 
HCC functions were identified in this module, including collagen type I, alpha 2 (Col1a2), matrix metallo-
peptidase 14 (Mmp14), frizzled-related protein (Frzb), dickkopf WNT signalling pathway inhibitor 3 (Dkk3), 
glutamate-ammonia ligase (Glul), and cyclin D1 (Ccnd1). The functions of these genes include extracellular 
matrix formation/angiogenesis (Col1a2 and Mmp14), inhibitors of Wnt signalling (Frzb and Dkk3), and regu-
lation of Wnt target genes (Glul and Ccnd1). The expression levels of these genes were significantly correlated 
with plasma Fgf21 levels (Fig. 4e), demonstrating that plasma Fgf21 level is associated with HCC-related sig-
nalling. Moreover, the identification of predicted upstream regulators further confirmed the association of this 
module with hepatocellular carcinoma (Fig. 4d): predicted inhibition of hepatocyte nuclear factor 4α and 1α 
(HNF4A and HNF1A), both are tumor suppressor regulators, while rapamycin-insensitive companion of mTOR 
(RICTOR) and mitogen-activated protein 4 kinase 4 (MAP4K4), factors involved in cancer development, were 
activated. X-box binding protein (XBP1) was also identified as one of the top upstream regulators.
The elevated plasma Fgf21 levels in young animals without accumulation of IHTG were related 
to the up-regulation of lipid metabolism by PPARα, PPARGC1α and PPARγ. To elucidate the 
functions of the genes associated with the elevated Fgf21 plasma level at young age without accumulation of 
IHTG, WGCNA analysis was performed with the inclusion of the 6-month-old animals. For this purpose, we 
searched for a gene module that was significantly associated with plasma Fgf21, but not with IHTG, and we 
found that module MEgreen (1286 genes) fulfilled this criterion (Supplementary Fig. S5a). This module has a 
significant correlation with Fgf21 (r = 0.44, p < 0.0001), but not with IHTG (r = 0.004, p = 1). To screen for the 
AUROC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
All time points
 0.77 (0.67–0.87) 91.4 57.1 60.4 90.3 71.4
Without 6 months old
 0.84 (0.74–0.94) 88.6 73.5 77.5 86.2 81.2
Table 1. Overall performance of plasma Fgf21 levels for the diagnosis of NAFLD.
Fgf21 in combination with Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Plasma ALT 80.0 97.1 96.6 82.5 88.4
Plasma CK-18 82.9 79.4 80.6 81.8 81.2
Body weight 80.0 94.1 93.3 82.1 87.0
Table 2. NAFLD diagnosis performance of plasma Fgf21 in combination with other markers.
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genes strongly correlated with the plasma Fgf21, we filtered for the genes with a correlation coefficient larger 
than 0.4. IPA of biological functions revealed that these genes play a role in lipid metabolism (top 3 functions/
regulators are listed in Supplementary Fig. S5b) and IPA identified peroxisome proliferator-activated receptor 
α (PPARα ), peroxisome proliferator-activated receptor γ coactivator 1-α (PPARGC1α ), and PPARγ as the pre-
dicted upstream regulators.
NRF2 and PPARα targets, pathways differentially up-regulated by NAFLD, were linked to 
Fgf21. Next, to determine the relevance of Fgf21 in the NAFLD-related pathways, we first identified the 
pathways differentially regulated in the animals with NAFLD by performing GSEA. Then, we explored the 
Figure 4. Liver biological processes associated with plasma Fgf21 level. (a) Heatmap depicting the 
correlation between gene modules (in rows) and phenotypes (in columns). The top values in each cell represents 
the correlation coefficient between the module and phenotype with the correlation p-value in parentheses. Red 
and green color represents positive and negative correlation, respectively. Correlation between plasma Fgf21 
levels and hepatic expressions of Cd36 (b) and Klb (c). (d) Biological processes and regulators associated with 
MEturquoise, which is the most significant modules correlated with plasma Fgf21. Significant liver-specific 
functions and upstream regulators are reported in p-values and z-scores. Positive and negative z-score represent 
predicted activation and inhibition, respectively. (e) Correlation between plasma Fgf21 and expression levels 
of hepatocellular carcinoma-related genes within MEturqouise, which included genes related to extracellular 
matrix formation and angiogenesis (Col1a2 and Mmp14), inhibition of Wnt signalling (Frzb and Dkk3), and 
downstream target of Wnt signalling (Glul and Ccnd1). r values were calculated with Pearson’s correlations and 
their significance are indicated in the parentheses.
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differentially regulated pathways in NAFLD for their link to Fgf21. The gene expression data of 12, 24, and 
28-month old animals were analysed with the exclusion of the CR group, since the latter group has a markedly 
different gene expression profile19. Forty-five animals were included in the microarray analysis (32 and 13 ani-
mals, with and without NAFLD, respectively). The GSEA results (based on FDR q value < 0.01), presented in 
Tables 3 and 4, revealed that 18 and 12 pathways were up- and down-regulated in NAFLD, respectively (lists of 
pathways with FDR q value < 0.05 is available in Supplementary Tables S4 and S5). The up-regulated pathways 
were dominated by pathways related to oxidative stress (nuclear factor (erythroid-derived 2)-like 2 or NRF2 
targets, glutathione metabolism), energy and lipid metabolism (PPARα targets, oxidative phosphorylation and 
electron transport chain and fatty acid metabolism). The down-regulated pathways included various complement 
cascades pathways. Interestingly, NRF2 and PPARα targets, the 2 most significantly enriched up-regulated path-
ways, contained genes that have been previously identified for their strong correlation with IHTG35: NAD(P)H 
dehydrogenase quinone 1 (Nqo1), sulfiredoxin 1 (Srxn1), cell death-inducing DFFA-like effector a (Cidea) and c 
(Cidec). Genes in the core enrichment of NRF2 and PPARα targets are listed in Supplementary Tables S6 and S7. 
The gene expression levels of these genes were analysed for their correlation with IHTG, which revealed highly 
significant correlations (p < 0.0001; Fig. 5a,b). Although not as strong, the expression levels of these genes were 
also significantly correlated with the plasma Fgf21 levels. Thus, the differentially regulated PPARα and NRF2 
target genes were pointed out to be the link between plasma Fgf21 levels and IHTG content during NAFLD.
Notably, MAPK targets was also among the pathways enriched in the NAFLD-differentially regulated pathway 
(full list of genes in core enrichment of MAPK targets in Supplementary Table S8). This is in line with the finding 
of MAP4K4 activation in Fig. 4d. The top MAPK target genes, protein phosphatase 2, regulatory subunit A, beta 
(Ppp2r1b) and dual specificity phosphatase 3 (Dusp3), showed significant correlations to both IHTG content and 
Enriched up-regulated pathways NES* FDR q-value
NRF2 TARGETS 2.617 0.00000
PPARA TARGETS 2.404 0.00000
WP1248 OXIDATIVE PHOSPHORYLATION 2.328 0.00000
WP295 ELECTRON TRANSPORT CHAIN 2.299 0.00068
KEGG OXIDATIVE PHOSPHORYLATION 2.260 0.00081
KEGG LYSOSOME 2.223 0.00090
WP1269 FATTY ACID BETA OXIDATION 2.208 0.00097
KEGG FATTY ACID ELONGATION 2.180 0.00135
KEGG FATTY ACID DEGRADATION 2.146 0.00210
MITOCHONDRIAL TRANSLATION 2.113 0.00337
MITOCHONDRIAL TRANSLATION TERMINATION 2.102 0.00344
MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES 2.079 0.00418
KEGG GLUTATHIONE METABOLISM 2.052 0.00625
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC 
COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS 2.048 0.00629
SPHINGOLIPID METABOLISM 2.032 0.00775
AQUAPORIN MEDIATED TRANSPORT 2.025 0.00786
KEGG SYNAPTIC VESICLE CYCLE 2.020 0.00795
MITOCHONDRIAL TRANSLATION INITIATION 2.003 0.00937
Table 3.  List of the significantly enriched up-regulated pathways in NAFLD. * Normalised enrichment score 
(NES); a statistical test for gene set enrichment.
Enriched down-regulated pathways NES FDR q-value
WP449 COMPLEMENT AND COAGULATION CASCADES − 2.496 0.00000
KEGG COMPLEMENT AND COAGULATION CASCADES − 2.496 0.00000
KEGG SELENOCOMPOUND METABOLISM − 2.229 0.00018
FORMATION OF FIBRIN CLOT CLOTTING CASCADE − 2.272 0.00024
WP200 COMPLEMENT ACTIVATION CLASSICAL PATHWAY − 2.219 0.00028
BIOC INTRINSICPATHWAY − 2.081 0.00213
COMMON PATHWAY 2.086 0.00226
REGULATION OF COMPLEMENT CASCADE − 2.066 0.00304
COMPLEMENT CASCADE − 2.023 0.00428
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE − 1.995 0.00606
WP460 BLOOD CLOTTING CASCADE − 1.962 0.00857
INTRINSIC PATHWAY − 1.963 0.00928
Table 4. List of the significantly enriched down-regulated pathways in NAFLD.
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plasma Fgf21 levels (Fig. 5c). Therefore, this signifies the association of plasma Fgf21 with liver cancer-related 
signalling.
Gene expression response to PPARα activation demonstrates its dysregulation in 
NAFLD. Based on the essential role of PPARα in lipid homeostasis, we further investigated whether the dys-
regulation of PPARα in NAFLD extends to an altered response when the system is challenged. To examine the 
response of PPARα , prior to each sacrifice the PPARα agonist Wy-14,643 (Wy) substance was administered to half 
of the mice of each intervention group, while the other half of the group received mock treatment. A number of 
PPARα target genes, including Fgf2136,37, were analysed by Q-PCR, namely monoacylglycerol O-acyltransferase 1 
(Mogat1), G0/G1 switch 2 (G0s2), acyl-CoA thioesterase 3 (Acot3), hydroxymethyl glutary coenzyme A reductase 
(Hmgcr) (Fig. 6a–e). These genes were selected to represent different functions regulated by PPARα (lipogenesis: 
Mogat1; lipolysis: G0s2; fatty acid oxidation: Acot3; cholesterol metabolism: Hmgcr), As shown in Fig. 6a, Wy 
treatment led to induced hepatic Fgf21 expression and the 2-way ANOVA test indicated an interaction between 
NAFLD and the Wy response. Intriguingly, animals with NAFLD exhibited an augmented response to the treat-
ment. Similarly to Fgf21 expression, the induction of Mogat1 and Hmgcr expression levels were stronger in the 
animals with NAFLD (Fig. 6b,e). However, not all genes demonstrated the stochastic response to Wy treatment. 
G0s2 and Acot3 expression levels were similarly up-regulated regardless of the presence of NAFLD (Fig. 6c,d). The 
expression of Pparα itself was also examined and the results in Fig. 6f show that the stimulation of PPARα did 
not differ between the animals with and without NAFLD. Although NAFLD presence did not alter the response 
to Wy treatment of all PPARα target genes, the expression profiles of Fgf21, Mogat1 and Hmgcr underscore the 
dysregulation PPARα signalling pathway in NAFLD.
Figure 5. The differentially regulated pathways in NAFLD were reflected by plasma Fgf21 levels. (a) Stress 
induced by NAFLD may activate NRF2, PPARα and MAPK, and the expression of their target genes. The 
expression levels of the NRF2 (b) PPARα (c) and MAPK (d) target genes were strongly correlated with IHTG 
and more modestly with plasma Fgf21 levels (in black and red color, respectively). r values were calculated with 
Pearson’s correlations and their significance are indicated in the parentheses.
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Discussion
In our mouse aging cohort, NAFLD development started at middle-age in Control (C)- and medium-fat 
(MF)-exposed mice, but not in the calorie restricted (CR)-fed animals, which stayed lean over time. The preva-
lence of NAFLD in the ad libitum C- and MF-fed groups increased during aging, which reflects weight gain and 
aging as risk factors for developing NAFLD38. In this study, we applied a long-term exposure to a less extreme 
diet compared to previous studies16,17 by using a 25E% medium-fat diet to mimic the slow onset of NAFLD in the 
human population, which did not induce severe NAFLD. We assessed this by analysing the liver fibrosis marker, 
4-hydroxyproline content, and observed a lower prevalence of liver fibrosis, compared to liver steatosis or benign 
NAFLD.
The analysis of plasma Fgf21 levels in the different intervention groups and ages suggests that there is an 
age-effect on plasma Fgf21 levels, although we did not observe a diet-dependent effect on plasma Fgf21 levels. 
We found that at the age of 6 months, some of the mice displayed a high level of plasma Fgf21 in the absence of 
elevated IHTG levels. A previous study in children has also revealed a lack of correlation between serum FGF21 
and NAFLD parameters39, moreover another study showed an inverse correlation between FGF21 and hepatic 
damage40. The addition of serum FGF21 in a NAFLD diagnostic model for children and adolescent also failed to 
improve the diagnostic performance32. An age of 6 months in mice is equivalent to mature adult age (~30 years 
old in human)41 and does not correspond to a developmental period in childhood. However, both mice and 
human data support either an absence of correlation or different correlation between plasma Fgf21 and NAFLD 
in younger age groups. Overall, our results reveal that, with the exception of the 6-month-old animals, plasma 
Fgf21 levels significantly correlated with IHTG content and performed well as a plasma marker for NAFLD diag-
nosis. This is in agreement with the results of previous studies in humans10,11.
The pathogenesis of NAFLD is attributed to a multi-hit process that includes lipotoxicity, oxidative stress and 
endoplasmic reticulum (ER) stress. Liver fat accumulation involves excess fatty acid supply to the liver, which 
triggers fatty acid oxidation and, consequently, oxidative stress from microsomal enzymes and ER stress. We 
found that NRF2 and PPARα targets were the most significantly enriched up-regulated pathways in the animals 
with NAFLD. NRF2 acts as a protective measure against oxidative stress, by producing antioxidant proteins. 
Meanwhile, PPARα activation is crucial for maintaining the homeostasis of fatty acid metabolism by increasing 
mitochondrial β -oxidation, thereby reducing the potential for fatty acid-induced lipotoxicity42. In addition, the 
WGCNA followed by pathway analysis pointed XBP1 out as one of the predicted upstream regulators of Fgf21. 
The elevated expression of FGF21 has been described as a counteractive mechanism for ER stress, by modulating 
lipid metabolism43–45. Therefore, the up-regulation of Fgf21 in NAFLD appears to be a simultaneous protection 
against lipotoxicity, oxidative stress and ER stress in NAFLD.
Intriguingly, we found that plasma Fgf21 levels at young age were related to fatty acid oxidation (L-carnitine 
shuttle and β -oxidation), which also corresponds to PPARα activation. While this seems to be contradictory with 
the idea of PPARα activation as a protective measure for fatty liver, both mouse and human studies have reported 
that the increased mitochondrial activity and β -oxidation do not necessarily reflect an efficient electron transport 
chain46–48. The authors found that the electron transport chain in subjects with hepatic steatosis and/or obesity is 
inefficient46–48. Therefore, it is worthwhile noting that, despite the up-regulated fatty acid oxidation in both young 
animals without NAFLD and old animals with NAFLD, the up-regulation in old animals with NAFLD measure-
ment might lead to perturbing consequences, such as hepatic oxidative stress.
The in vivo PPARα challenge performed in this study provides a novel insight into the ability of maintaining 
metabolic homeostasis. A dynamic measurement by using system perturbation or challenge tests are likely more 
valuable to define metabolic health or resilience, compared to more static measurements49. By performing the 
PPARα agonist treatment, we demonstrate that the PPARα response at the transcriptional level is partially altered 
in the presence of NAFLD. It appears that liver fat is the burden of the liver’s plasticity of lipid metabolism. A 
similar notion was reported by Hyotylainen and co-workers, showing that high liver fat markedly hampers the 
ability of the liver to adaptively regulate metabolism to meet the excessive demands on basic liver functions. As 
a consequence, individuals with NAFLD may be more vulnerable to various metabolic stressors on the liver50. 
This underlines that, although hepatic steatosis is considered benign (first hit), when the metabolic system faces 
a challenge (second/multiple hits), the ability to maintain or regain homeostasis might have been compromised.
Furthermore, we revealed the association between plasma Fgf21 and transcriptional changes related to hepa-
tocellular carcinoma (HCC) development. The predicted regulators (HNF1A, HNF4A, RICTOR, MAP4K4), 
functional pathways and genes (Wnt target genes Ccnd1 and Glul) associated with plasma Fgf21 suggest dysreg-
ulations of metabolic and proliferative pathways51,52, which are characteristics of a benign hepatocellular tumor. 
Although these dysregulations alone were not sufficient to induce carcinogenesis, it likely increases the suscep-
tibility to HCC development. In line with this hypothesis, a pre-malignant stage in NAFLD has been shown to 
denote stress, inflammation and even apoptosis, which pre-condition and initiate pro-oncogenic signals53. This is 
supported by the evidence that both liver expression and circulating levels of FGF21 are increased in patients with 
hepatitis, cirrhosis and hepatocarcinoma54. Therefore, the population would likely benefit from the use of plasma 
Fgf21 as a biomarker of an early stage of NAFLD.
Although the association between plasma Fgf21 and HCC-related function is not as strong as its performance 
in reflecting the benign NAFLD stage, plasma Fgf21 might be beneficial in improving the performance of bio-
markers for advanced stages of NAFLD. This has been suggested in the study of a NASH biomarker, that for the 
purpose of defining the stages of NASH, plasma CK-18 performs better than FGF21, but adding FGF21 to the 
CK-18 model significantly improved the performance14. We evaluated the combined analysis of plasma Fgf21 and 
CK-18 to detect NAFLD in our study, but it did not result in a higher accuracy compared to merely Fgf21 analysis. 
A plausible explanation for this observation is that our mice cohort modelled a rather mild NAFLD development, 
so that the addition of plasma CK-18, which represents advanced stages of NAFLD, did not effectively improve 
the analysis.
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Figure 6. The response to PPARα challenge test showed that the presence of NAFLD partially altered the 
response at the gene expression levels. (a) Fgf21; (b) Mogat1; (c) G0s2; (d) Acot3; (e) Hmgcr; and (f) Pparα. 
The effect of PPARα agonist and NAFLD, as well as any interaction between them, were analysed using two-way 
ANOVA.
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In this study, we discovered that the expression level of Klb, a critical co-receptor of the FGF receptors, was 
negatively correlated with plasma Fgf21, IHTG and body weight. In addition, the liver expression levels of the FGF 
receptors Fgfr2 and Fgfr4 showed similar patterns, although the declining expression levels were not as strong as 
observed for Klb. FGFR2 and FGFR4 proteins, along with FGFR1, have been shown to form a transmembrane 
complex with β -klotho to mediate the effects of FGF21 in adipocytes55. Although the type of FGF receptor that 
forms a complex with β -klotho protein in the liver is still unclear, this observation underlines the growing notion 
that metabolic system might develop a resistance to mediate the beneficial effect of Fgf21. The Fgf21 resistance 
due to its co-receptor alteration is an essential issue to be addressed during the further development of FGF21 as 
a novel pharmacological agent for metabolic diseases56. Both human and mice studies have reported increased 
FGF21 gene expression or circulating protein levels with obesity and/or metabolic syndrome57–59. One of these 
studies also demonstrated that the diet-induced obese mice with an elevated endogenous level of Fgf21 responded 
poorly to acute exogenous Fgf21 administration59. Since Klb plays a critical role in mediating Fgf21’s metabolic 
activity34,60, the declining Klb expression that occurs over a long-term obesity and/or hepatic steatosis develop-
ment might result in Fgf21 resistance. Therefore, in order to assess the possibility of resistance to FGF21 treat-
ment, the consequence of the down-regulation of critical FGF21 receptors/co-receptors in the liver on sensitivity 
to endo- and exogenous FGF21 warrants further investigation. It is worthwhile noting that, in the acute induction 
of obesity in mouse model, Klb expression was not altered in the obese state59.
Taken together, in this study, we demonstrate that plasma Fgf21 levels strongly reflects liver fat accumulation, 
confirming its potential as NAFLD marker. However, this association is age-dependent and does not apply at the 
age of 6 months in the C57BL/6J mice. The molecular link between plasma Fgf21 and IHTG levels was associated 
with dysregulation of both metabolic and cancer-related pathways. The up-regulated Fgf21 levels in NAFLD 
appears to be a measure to maintain homeostasis against the adverse effects in NAFLD, e.g. lipotoxicity, oxidative 
stress and endoplasmic reticulum stress. The elevated plasma Fgf21 is also associated with declining expression 
of Klb, its crucial co-receptor, which suggests a resistance to Fgf21. Therefore, although liver fat accumulation is a 
benign stage of NAFLD, the liver is likely more vulnerable to metabolic stressors and progress to end-stage liver 
disease. The in vivo PPARα challenge further demonstrates the dysregulation of PPARα signalling in the presence 
of NAFLD, which results in a stochastically increasing hepatic expression of Fgf21. In conclusion, Fgf21 plasma 
levels reflect liver fat accumulation and dysregulation of metabolic pathways at a transcriptional level in the liver 
of C57BL/6J mice.
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